165 related articles for article (PubMed ID: 1328554)
1. Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
Giamarellou H; Voutsinas D; Xirouchaki E
J Chemother; 1992 Feb; 4(1):12-5. PubMed ID: 1328554
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
3. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
Wallrauch C; Voss A; Milatovic D; Braveny I
Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
Doebbeling BN; Pfaller MA; Bale MJ; Wenzel RP
Eur J Clin Microbiol Infect Dis; 1990 Apr; 9(4):298-301. PubMed ID: 2112467
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
[TBL] [Abstract][Full Text] [Related]
12. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
Wise R; Andrews JM; Brenwald N
J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of HSR-903, a new quinolone.
Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
Ling TK; Liu EY; Cheng AF
Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
[TBL] [Abstract][Full Text] [Related]
16. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
McCarter YS; Mazens-Sullivan MF; Bartlett RC
Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to newer antimicrobials.
Matsuyama JR; Beail B; Wallis C; Zeleznik D; Tartaglione T
Clin Pharm; 1991 Jul; 10(7):544-8. PubMed ID: 1860303
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
[TBL] [Abstract][Full Text] [Related]
19. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Wise R; Brenwald NP; Andrews JM; Boswell F
J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of T-3761, a new fluoroquinolone.
Muratani T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
